Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) EPS (Weighted Average and Diluted) (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$3.38 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 62.73% to -$3.38 in Q3 2025 year-over-year; TTM through Sep 2025 was -$9.18, a 11.3% increase, with the full-year FY2024 number at -$1.43, down 13.49% from a year prior.
  • EPS (Weighted Average and Diluted) was -$3.38 for Q3 2025 at Lyra Therapeutics, up from -$5.51 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.09 in Q4 2022 to a low of -$9.07 in Q3 2024.
  • A 5-year average of -$1.36 and a median of -$0.44 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 91.43% in 2022, then plummeted 3259.26% in 2024.
  • Lyra Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.05 in 2021, then surged by 91.43% to -$0.09 in 2022, then plummeted by 111.11% to -$0.19 in 2023, then grew by 15.79% to -$0.16 in 2024, then crashed by 2012.5% to -$3.38 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's EPS (Weighted Average and Diluted) are -$3.38 (Q3 2025), -$5.51 (Q2 2025), and -$0.13 (Q1 2025).